Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Am Coll Surg ; 234(2): 115-120, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1713820

ABSTRACT

BACKGROUND: Living donor liver transplantation (LDLT) continues to be the primary modality of liver transplantation in Asia, but it accounts for about 5% of all liver transplantations in the US. ABO incompatibility is the primary reason motivated donors are declined. Although kidney paired exchanges are common, liver paired exchange (LPE) is still evolving in the US. STUDY DESIGN: This is a retrospective review (between January 1, 2019, and July 31, 2021) of our initial experience with LPE. RESULTS: A total of 10 LPEs (20 LDLTs) were performed during the study period. Seven LPEs were initiated by a nondirected O donor. The other 3 pair sets involved 1 ABO compatible and 1 ABO incompatible pair. Transplantations in a pair set were completed within a mean of 4.8 (range 1-14) days of each other. All 20 donors are doing well with no major complications at 12.7 (range 1-20) months. Seventeen of 20 recipients are alive and have good allograft function. One recipient died in the early postoperative period. Two late deaths of patients with functioning allografts were due to COVID-19 (at 8 months) and peritoneal carcinomatosis and gram-negative sepsis (at 9 months). CONCLUSIONS: LPE is feasible in a high-volume LDLT center and is a useful option to increase LDLT by overcoming ABO incompatibility. Nondirected donors can be utilized to initiate an LPE.


Subject(s)
Liver Transplantation/statistics & numerical data , Living Donors/statistics & numerical data , Tissue and Organ Procurement/methods , ABO Blood-Group System , Adolescent , Adult , Aged , Blood Group Incompatibility , COVID-19/mortality , Cause of Death , Female , Humans , Kidney , Living Donors/supply & distribution , Male , Middle Aged , Postoperative Complications/etiology , Retrospective Studies , Tissue and Organ Procurement/statistics & numerical data , Transplant Recipients/statistics & numerical data , Young Adult
2.
Pediatr Transplant ; 26(2): e14162, 2022 03.
Article in English | MEDLINE | ID: covidwho-1462869

ABSTRACT

BACKGROUND: The COVID-19 pandemic has affected all aspects of the US healthcare system, including liver transplantation. The objective of this study was to understand national changes to pediatric liver transplantation during COVID-19. METHODS: Using SRTR data, we compared waitlist additions, removals, and liver transplantations for pre-COVID-19 (March-November 2016-2019), early COVID-19 (March-May 2020), and late COVID-19 (June-November 2020). RESULTS: Waitlist additions decreased by 25% during early COVID-19 (41.3/month vs. 55.4/month, p < .001) with black candidates most affected (p = .04). Children spent longer on the waitlist during early COVID-19 compared to pre-COVID-19 (140 vs. 96 days, p < .001). There was a 38% decrease in liver transplantations during early COVID-19 (IRR 0.62, 95% CI 0.49-0.78), recovering to pre-pandemic rates during late COVID-19 (IRR 1.03, NS), and no change in percentage of living and deceased donors. White children had a 30% decrease in overall liver transplantation but no change in living donor liver transplantation (IRR 0.7, 95% CI 0.50-0.95; IRR 0.96, NS), while non-white children had a 44% decrease in overall liver transplantation (IRR 0.56, 95% CI 0.40-0.77) and 81% decrease in living donor liver transplantation (IRR 0.19, 95% CI 0.02-0.76). CONCLUSIONS: The COVID-19 pandemic decreased access to pediatric liver transplantation, particularly in its early stage. There were no regional differences in liver transplantation during COVID-19 despite the increased national sharing of organs. While pediatric liver transplantation has resumed pre-pandemic levels, ongoing racial disparities must be addressed.


Subject(s)
COVID-19 , Health Services Accessibility/trends , Healthcare Disparities/trends , Liver Transplantation/trends , Waiting Lists/mortality , Adolescent , Child , Child, Preschool , Female , Healthcare Disparities/ethnology , Humans , Infant , Infant, Newborn , Living Donors/statistics & numerical data , Male , Registries , Retrospective Studies , United States
3.
Biomed Res Int ; 2020: 5703963, 2020.
Article in English | MEDLINE | ID: covidwho-878206

ABSTRACT

INTRODUCTION: SARS-CoV-2 is a virus that causes a potentially deadly syndrome that affects especially the respiratory tract. Kidney-transplanted patients are immunosuppressed and more susceptible to viral infections. We have examined our transplantation activity to explore the future role of kidney transplantation from deceased and living donors in COVID-19 era. Patients and Methods. The activity of our transplant center of Naples (one of the two transplant centers in Campania, South Italy) continued during the COVID-19 pandemic. We have analysed the kidney transplants carried out between March 9 and June 9, 2020, comparing these data with the numbers of procedures performed in the two previous years. Moreover, we have considered the possibility of performing living donor transplants during a worldwide pandemic. RESULTS: From March 9, 2020, when the Italian lockdown begun, till June 9, 2020, five kidney transplants have been performed at our transplant center in Naples, all from deceased donors. The donors and the recipients have been screened for COVID-19 infection, and the patients, all asymptomatic, followed strict preventive measures and were fully informed about the risks of surgery and immunosuppression during a pandemic. All the transplanted patients remained COVID negative during the follow-up. The number of transplants performed has been constant compared to the same months of 2018 and 2019. In agreement with the patients, we decided to postpone living donor transplants to a period of greater control of the SARS-CoV-2 spread in Italy. CONCLUSION: Deceased donor kidney transplantation should continue, especially in a region with moderate risk, like Campania, with a more careful selection of donors and recipients, preferring standard donors and recipients without severe comorbidities. Living donor transplantation program, instead, should be postponed to a period of greater control of the SARS-CoV-2 spread, as it is an elective surgery and its delay does not determine additional risks for patients.


Subject(s)
COVID-19/epidemiology , Kidney Transplantation/statistics & numerical data , COVID-19/diagnosis , COVID-19/prevention & control , Female , Humans , Italy/epidemiology , Kidney Transplantation/psychology , Living Donors/psychology , Living Donors/statistics & numerical data , Male , Middle Aged , Risk Factors , SARS-CoV-2/isolation & purification
4.
Pediatr Nephrol ; 36(1): 143-151, 2021 01.
Article in English | MEDLINE | ID: covidwho-800908

ABSTRACT

BACKGROUND: In March 2020, COVID-19 infections began to rise exponentially in the USA, placing substantial burden on the healthcare system. As a result, there was a rapid change in transplant practices and policies, with cessation of most procedures. Our goal was to understand changes to pediatric kidney transplantation (KT) at the national level during the COVID-19 epidemic. METHODS: Using SRTR data, we examined changes in pediatric waitlist registration, waitlist removal or inactivation, and deceased donor and living donor (DDKT/LDKT) events during the start of the disease transmission in the USA compared with the same time the previous year. RESULTS: We saw an initial decrease in DDKT and LDKT by 47% and 82% compared with expected events and then a continual increase, with numbers reaching expected prepandemic levels by May 2020. In the early phase of the pandemic, waitlist inactivation and removals due to death or deteriorating condition rose above expected values by 152% and 189%, respectively. There was a statistically significant decrease in new waitlist additions (IRR 0.49 0.65 0.85) and LDKT (IRR 0.17 0.38 0.84) in states with high vs. low COVID activity. Transplant recipients during the pandemic were more likely to have received a DDKT, but had similar calculated panel-reactive antibody (cPRA) values, waitlist time, and cause of kidney failure as before the pandemic. CONCLUSIONS: The COVID-19 pandemic initially reduced access to kidney transplantation among pediatric patients in the USA but has not had a sustained effect.


Subject(s)
Kidney Transplantation/statistics & numerical data , Living Donors/statistics & numerical data , Waiting Lists/mortality , Adolescent , Adult , COVID-19/epidemiology , Child , Child, Preschool , Female , Health Services Accessibility/statistics & numerical data , Humans , Infant , Infant, Newborn , Male , Middle Aged , Pandemics , Registries , SARS-CoV-2 , United States/epidemiology , Young Adult
5.
Transplant Proc ; 52(9): 2607-2613, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-708645

ABSTRACT

The concerns generated by coronavirus disease 2019 (COVID-19) pandemic are having profound impact on solid organ transplantation (SOT). Non-pharmaceutical interventions (NPI) are currently the only measures available to contain COVID-19 in the general population and in more vulnerable recipients of any organ transplant. In this cross-sectional case control study from a patient survey undertaken in 2 transplant centers (TxC) in the Kingdom of Saudi Arabia and Italy, we aimed to appraise awareness of the NPI implemented by respective these governments. We have also evaluated the impact of COVID-19 on our kidney transplant (KT) recipients and a control group of kidney living donors (KLD). In our series, there were zero cases of COVID-19 among 111 KT recipients and 70 KLD of the control group. Demography, transplant type, immunosuppression regimes, and, importantly, the different COVID-19 prevalence in the 2 regions of the TxC did not appear to influence incidence of COVID-19 in our KT recipients. The absence of COVID-19 cases in our series was unexpected. Our findings suggest that awareness of NPI is associated with a successful containment of COVID-19 in vulnerable, immunosuppressed KT recipients.


Subject(s)
Betacoronavirus/immunology , Coronavirus Infections/epidemiology , Immunocompromised Host/immunology , Kidney Transplantation/adverse effects , Pneumonia, Viral/epidemiology , Postoperative Complications/epidemiology , Adult , COVID-19 , Case-Control Studies , Coronavirus Infections/immunology , Cross-Sectional Studies , Female , Humans , Incidence , Italy/epidemiology , Living Donors/statistics & numerical data , Male , Middle Aged , Pandemics , Pneumonia, Viral/immunology , Postoperative Complications/immunology , Postoperative Complications/virology , Prevalence , SARS-CoV-2 , Saudi Arabia/epidemiology , Tissue and Organ Harvesting/adverse effects , Tissue and Organ Procurement/statistics & numerical data
6.
Transpl Infect Dis ; 22(5): e13384, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-610833

ABSTRACT

COVID-19 is now a pandemic with increasing numbers of cases and deaths. In addition to the economic and social damage caused by COVID-19 outbreak prolongation, damage caused by delayed treatment of other diseases such as severe cirrhosis is also serious. We aimed to describe the effect of COVID-19 on the number of liver transplants (LT) in South Korea. The number of LT performed in Korea during the Middle East Respiratory Syndrome (MERS) outbreak, and the COVID-19 pandemic was compared with the average number of LT performed in the past 5 years. There were 108.5 cases of LT performed per month during the MERS outbreak. It was 11% lower than the average of 122.8 cases per month for the last 5 years. LDLT and DDLT decreased by 13% to 75.3 cases and by 7.5% to 33.2 cases per month during the MERS epidemic, respectively. From January to March 2020 (COVID-19 outbreak), the number of LT did not decrease significantly. The lockdown caused by COVID-19 did not affect the number of liver transplants in Korea. Establishing a safe process and procedure of liver transplantation within safe boundaries can be beneficial in reducing the side effects of lockdown and saving patients' lives.


Subject(s)
COVID-19/prevention & control , Communicable Disease Control/standards , Coronavirus Infections/prevention & control , End Stage Liver Disease/surgery , Liver Transplantation/statistics & numerical data , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , End Stage Liver Disease/mortality , Humans , Liver Transplantation/methods , Liver Transplantation/standards , Living Donors/statistics & numerical data , Middle East Respiratory Syndrome Coronavirus/pathogenicity , Pandemics/prevention & control , Republic of Korea/epidemiology , SARS-CoV-2/pathogenicity , Waiting Lists/mortality
SELECTION OF CITATIONS
SEARCH DETAIL